Skip to main content

GVHD Archives

Treatment approved for patients with acute graft-versus-host disease

Jun. 13, 2019—The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.

Read more


Skin diseases study uses crowdsourcing to gather data

Feb. 21, 2019—In 1906, English statistician Francis Galton happened to visit a livestock fair where fairgoers were invited to guess the dressed weight of an ox scheduled for imminent slaughter. Some 800 attendees took part and afterwards Galton got hold of the contest data.

Read more


Using light to fight GVHD

Aug. 30, 2018—Extracorporeal photopheresis treatment for stem cell transplant-related complications produces a response in up to 60 percent of patients.

Read more


Targeting post-transplant diabetes

Apr. 12, 2012—Targeting diabetes that develops after a stem cell transplant may help moderate graft-vs.-host disease, an adverse effect of the procedure, and improve outcomes.

Read more


Recent Stories from VUMC News and Communications Publications

Keeping pace: Nashville, once a mid-size city with a Southern small-town feel, is experiencing explosive growth.

Vanderbilt Medicine

Keeping pace: Nashville, once a mid-size city with a Southern small-town feel, is experiencing explosive growth.

VUMC campus

VUMC campus

Vanderbilt University School of Medicine entrance

Vanderbilt University School of Medicine entrance

Vanderbilt University Adult Hospital with helipad

Vanderbilt University Adult Hospital with helipad

more